Humana (HUM) Stock Forecast & Price Target

$392.63

+6.23 (+1.61%)

(As of 07/26/2024 ET)

Humana - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 22 Analyst Ratings

Based on 22 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 13 have given a hold rating, and 9 have given a buy rating for HUM.

Consensus Price Target

$402.60
2.54% Upside

High Forecast	$579.00
Average Forecast	$402.60
Low Forecast	$310.00

According to the 22 analysts' twelve-month price targets for Humana, the average price target is $402.60. The highest price target for HUM is $579.00, while the lowest price target for HUM is $310.00. The average price target represents a forecasted upside of 2.54% from the current price of $392.63.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	12 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	10 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$402.60	$409.55	$424.50	$591.11
Forecasted Upside	2.54% Upside	13.60% Upside	15.91% Upside	19.33% Upside

Get Humana Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Medical Companies	S&P 500
Consensus Rating Score	2.41	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	2.54% Upside	3,123.40% Upside	9.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/24/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$396.00 ➝ $407.00	+5.02%
7/23/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$360.00 ➝ $360.00	-6.58%
7/15/2024	Truist Financial 1 of 5 stars		Boost Target	Hold ➝ Hold	$355.00 ➝ $400.00	+2.66%
6/26/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$392.00	+10.15%
6/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$374.00	+5.21%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
Get the Latest News and Ratings for HUM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$374.00	+8.31%
5/20/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$342.00 ➝ $376.00	+5.56%
4/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$415.00 ➝ $353.00	+14.10%
4/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$334.00 ➝ $326.00	+5.43%
4/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$415.00 ➝ $370.00	+17.07%
4/22/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$411.00 ➝ $381.00	+15.74%
4/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$413.00 ➝ $350.00	+11.78%
4/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $385.00	+24.47%
4/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$356.00 ➝ $310.00	+0.93%
3/22/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
3/13/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
1/26/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$550.00 ➝ $400.00	+10.46%
1/26/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$550.00 ➝ $430.00	+18.45%
1/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$595.00 ➝ $360.00	-10.54%
11/17/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$593.00 ➝ $575.00	+13.90%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$599.00 ➝ $579.00	+15.49%
4/27/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$640.00 ➝ $600.00	+18.70%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$647.00 ➝ $581.00	+21.91%
2/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$635.00 ➝ $575.00	+20.65%
11/7/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$547.00 ➝ $647.00	+17.20%
11/3/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$540.00 ➝ $640.00	+14.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:23 AM ET.

HUM Forecast - Frequently Asked Questions

What is Humana's forecast for 2024?: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $402.60, with a high forecast of $579.00 and a low forecast of $310.00.
Should I buy or sell Humana stock right now?: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There are currently 13 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.
Does Humana's stock price have much upside?: According to analysts, Humana's stock has a predicted upside of 9.99% based on their 12-month stock forecasts.
Has Humana been upgraded by Wall Street analysts recently?: Over the previous 90 days, Humana's stock had 1 upgrade by analysts.
What analysts cover Humana?: Humana has been rated by research analysts at Baird R W, Bank of America, Cantor Fitzgerald, Morgan Stanley, Piper Sandler, Robert W. Baird, TD Cowen, and Truist Financial in the past 90 days.
Do Wall Street analysts like Humana more than its competitors?: Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.